Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta‐analysis
International Journal of Cancer · 2025-12 · 157 (11) · 2334-2342
DOI: 10.1002/ijc.70024 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Cancer, online erschienen am 25.06.2025. Verfasst von Yufan Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Zhejiang, Hangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sarcoma, Myeloid. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Extramedullary disease (EMD) occurs in 1%–30% of acute myeloid leukemia (AML) patients and has been associated with adverse outcomes. However, the magnitude of its prognostic impact varies considerably across studies, possibly due to inconsistent terminology and diagnostic approaches. The definition of EMD in AML varies, typically employing three descriptors: EMD (comprehensive), extramedullary infiltration (EMI), and myeloid sarcoma/granulocytic sarcoma (MS/GS). This first comprehensive meta‐analysis precisely quantifies EMD's prognostic impact, revealing a significant effect on overall survival (OS) (HR = 1.49, 95% CI, 1.34–1.67, p < .001) and event‐free survival (EFS) (HR = 1.38, 95% CI, 1.03–1.84, p = .030). Importantly, our subgroup analyses demonstrate that prognostic impact varies significantly by EMD classification. The HR for EMI was 1.88 (95% CI, 1.52–2.31, p = .000); for EMD, it was 1.41 (95% CI, 1.20–1.66, p = .000); and for MS/GS, it stood at 1.18 (95% CI, 0.92–1.52, p = .188). Additionally, we analyzed the influence of EMD on the OS of AML patients undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT) and found that allo‐HSCT may mitigate EMD's negative prognostic impact (HR = 1.19, 95% CI, 0.97–1.46, p = .092; Heterogeneity: I 2 = 0.0%, p = .860), confirming and quantifying this therapeutic benefit through meta‐analysis for the first time. These findings highlight the need for standardized EMD definitions and suggest differential therapeutic approaches based on EMD subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Zhejiang, Hangzhou, People's Republic of China.
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, People's Republic of China.
- Department of Hematology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, People's Republic of China.
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Zhejiang, Hangzhou, People's Republic of China.
ORCID-Profile: Jie Sun
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lin, Y., Liu, P., Zhuang, Q., Deng, H., Liu, X., Wang, Y., Tong, H., Liu, A., & Sun, J. (2025). Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta‐analysis. International Journal of Cancer, 157(11), 2334-2342. https://doi.org/10.1002/ijc.70024
Vancouver
Lin Y, Liu P, Zhuang Q, Deng H, Liu X, Wang Y, et al. Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta‐analysis. International Journal of Cancer. 2025;157(11):2334-2342. doi:10.1002/ijc.70024
BibTeX
@article{Lin2025,
author = {Lin, Yufan and Liu, Ping and Zhuang, Qiqi and Deng, Haoren and Liu, Xin and Wang, Yan and Tong, Hongyan and Liu, Aichun and Sun, Jie},
title = {Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta‐analysis},
journal = {International Journal of Cancer},
year = {2025},
volume = {157},
number = {11},
pages = {2334--2342},
doi = {10.1002/ijc.70024}
}
EUVIMED